Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

UK JCVI Not Recommends Novartis's Meningitis B Vaccine Bexsero For Immunization

RELATED NEWS
Trade NVS now with 

Swiss drug maker Novartis AG (NVS: Quote), Wednesday said the UK Joint Committee on Vaccination and Immunisation or JCVI took an interim position to not recommend Bexsero vaccine for inclusion in the National Immunisation Programme, driven by evaluation based on cost-effectiveness assumptions. The company added that the JCVI does not feel that the decision is in the interest of the public.

Novartis said the JCVI made its evaluation before any pricing discussion with it and if the position is not changed, it will postpone Bexsero access.

In January 2013, the European Medicines Agency licensed Bexsero for active immunization of individuals from two months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.

Click here to receive FREE breaking news email alerts for Novartis AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After trending higher over the past several sessions, stocks showed a lack of direction throughout the trading day on Friday before closing roughly flat. A muted reaction to a highly anticipated speech by Federal Reserve Chair Janet Yellen contributed to the lackluster performance. Republican Scott Brown has significantly narrowed the gap in the race against incumbent New Hampshire Sen. Jeanne Shaheen, D-N.H., according to the results of a new WMUR Granite State Poll. On the heels of the violent clashes between local police and protestors in Ferguson, Missouri, Sen. Claire McCaskill, D-Mo., announced that she will hold a Senate hearing in September to examine the militarization of local police departments.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.